Skip to content

CRYO-1: Cryoablation in Elderly Breast Cancer Patients

Treatment of Elderly Patients With Early Stage Breast Cancer (CRYO-1): The Efficacy of Cryoablation In The Elderly – A Phase II Multicentre, Feasibility Study. - CRYO-1

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58281
Enrollment
61
Registered
2025-08-25
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast carcinoma, mammary carcinoma, malignant breast tumor, breast malignancy, carcinoma of the breast Breast cancer

Interventions

The intervention under study is breast tumor cryoablation. Under ultrasound guidance, a thin cryoprobe is inserted into the tumor. Through this probe, argon or nitrogen gas is circulated, creating ext

Sponsors

Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age = 70 yearsHistologically confirmed invasive breast cancerClinical stage cT1N0M0 based on mammography and ultrasoundER-positive, HER2-negative (IHC 0-1+ or 2+ with negative ISH), any PR statusPresence of concurrent DCIS is allowed if limited to <25% of the pre-NST biopsy, with no radiologic suspicion of an extensive componentUnifocal disease <2 cm, well visualized on ultrasound, with a minimum distance of =5 mm from the skin, nipple and thoracic wallAbility and willingness to comply with project requirementsPreoperative endocrine therapy is allowedWritten informed consent given by the subject

Exclusion criteria

Exclusion criteria: Pure DCIS lesions without invasive componentExtensive calcifications on imaging suggestive of widespread diseaseInvasive lobular carcinoma (as assessed by IHC)Triple-negative or HER2-positive subtype (defined as (IHC 3+ or ISH positive)History of ipsilateral breast cancer or DCISPrior ipsilateral radiotherapyInability to communicate in Dutch or English languagePlanned (e)migration or long-term stay abroad within one year after inclusion

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the safety and feasibility of cryoablation in this patient population. This will be assessed by:incidence and type of adverse events and complications up to 3 months post-procedure, classified according to CTCAE v5.0;technical success and procedural feasibility (complete treatment of the tumor, procedure performed as planned).Secondary outcomes include recovery, cosmetic outcomes, quality of life, and patient satisfaction.

Secondary

MeasureTime frame
Secondary outcomes include recovery, cosmetic outcomes, quality of life, and patient satisfaction.

Countries

Netherlands

Contacts

Public ContactI Stekelenburg

Antonius Ziekenhuis

i.stekelenburg@antoniusziekenhuis.nl0657835198

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026